JP Morgan Chase’s Turnstone Biologics TSBX Stock Holding History

JP Morgan Chase’s Portfolio TSBX Stock Details TSBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-158	Closed	-$57	–	7730
2025 Q2	$57	Sell	158 -38	-19%	-$13	﹤0.01%	6888
2025 Q1	$81	Sell	196 -3	-2%	-$1	﹤0.01%	6905
2024 Q4	$98	Buy	199 +41	+26%	+$20	﹤0.01%	7009
2024 Q3	$88	Sell	158 -6,683	-98%	-$10.3K	﹤0.01%	7021
2024 Q2	$17.9K	Buy	6,841 +671	+11%	+$1.92K	﹤0.01%	6162
2024 Q1	$16.2K	Buy	6,170 +1,948	+46%	+$5.58K	﹤0.01%	6269
2023 Q4	$10.7K	Hold	4,222	–	–	﹤0.01%	6385
2023 Q3	$16.6K	Buy	+4,222	New	+$37.6K	﹤0.01%	6111

JP Morgan Chase's TSBX Position: Q3 2025 in Review

JP Morgan Chase sold out of Turnstone Biologics (TSBX) in Q3 2025, closing a stake of 158 shares — an estimated $57 sold.

JP Morgan Chase first reported a position in TSBX in Q3 2023 and held it in 8 quarters. The position peaked at $17.9K in Q2 2024. 1 fund tracked by Wall St. Rank holds TSBX as of Q3 2025.

JP Morgan Chase reported no remaining Turnstone Biologics position as of Q3 2025 after selling out during the quarter.
JP Morgan Chase sold 158 Turnstone Biologics shares in Q3 2025, an estimated $57.
JP Morgan Chase first reported a position in Turnstone Biologics in Q3 2023 and held it in 8 quarters.
JP Morgan Chase's Turnstone Biologics position peaked at $17.9K in Q2 2024.
1 fund tracked by Wall St. Rank held Turnstone Biologics as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.